Home > Kristl Vonck, EAN 2019 – Neurostimulation in drug-resistant epilepsy
Epilepsy

Kristl Vonck, EAN 2019 – Neurostimulation in drug-resistant epilepsy

Published Online: July 5th 2019

We were fortunate to have the opportunity to catch-up with Kristl Vonck (Ghent University Hospital, Ghent, Belgium) at EAN 2019. She talked to us about the topic of her recently published article: Measuring the Effects of Neurostimulation in Drug-resistant Epilepsy and Depression.

Questions
1. How common is drug-resistant epilepsy? (0:04)
2. What neurostimulation methods are available for these patients? (0:30)
3. How can we identify which patients are most likely to respond to neurostimulation (2:25)?

Speaker disclosure: Kristl Vonck has received grant support, consultancy and speaker fees from LivaNova Inc. and Medtronic.

Filmed at the 5th Congress of the European Academy of Neurology (EAN), Oslo, Norway, June 2019.

Share this Video
Related Videos In Epilepsy
Epilepsy
Kimford Meador, AAN 2021: Fetal Antiseizure Medication in Pregnant Women with Epilepsy

It was a great pleasure to meet with Kimford Meador (Stanford University, Stanford, CA, USA) to discuss the effects and use of antiseizure medications during pregnancy, in women with epilepsy. The abstract entitled: ‘Fetal Antiseizure Medication Effects on Neuropsychological Outcomes at Age 3 Years in the MONEAD Study’ was presented at the American Academy of […]

Epilepsy
Kimford Meador, AAN 2021: Preliminary findings of the MONEAD Study

It was a great pleasure to meet with Kimford Meador (Stanford University, Stanford, CA, USA) to discuss the aims, design and preliminary findings from the MONEAD study, and what these results mean for treatment of epilepsy in pregnant women. The abstract entitled: ‘Fetal Antiseizure Medication Effects on Neuropsychological Outcomes at Age 3 Years in the […]

Epilepsy
Michael Sperling, AAN 2021: Post-hoc Analysis of Cenobamate for Uncontrolled Focal Seizures

We were delighted to speak with Michael Sperling (Thomas Jefferson University, Philadelphia, PA, USA) to discuss the recent post-hoc analysis of cenobamate for uncontrolled focal seizures, and its intended place in the treatment landscape for epilepsy. The abstract entitled: ‘Efficacy of Cenobamate for Uncontrolled Focal Seizures: Post-hoc Analysis of a Phase 3, Multicenter, Open-Label Study’ […]

Trending In Epilepsy:

Kimford Meador, AAN 2021: Fetal Antiseizure Medication in Pregnant Women with Epilepsy
Epilepsy
    • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72